Glucocorticoid receptor expression in multiple myeloma patients is a predictor of survival
Alexander Pozhitkov1, Michael Rosenzweig1, Flavia Pichiorri1
1City Hope National Medical Center, Duarte, CA, USA.
Abstract:
Multiple myeloma (MM) is a blood neoplasia characterized by abnormal proliferation of plasma cells. Various treatments such as stem cell transplant (SCT), proteasome inhibitors, immune-modulating drugs, monoclonal antibodies and selective inhibitors of nuclear export have been routinely used to treat MM. However, relapse and treatment resistance are common problems in MM patients. Treatments are enhanced by Dexamethasone (Dex), a synthetic steroid that activates the glucocorticoid receptor (GR) which leads to apoptosis. To evaluate the potential impact of GR expression on overall survival, MM patient data from the CoMMpass study of 650 patients were analyzed. Multivariate modeling results show that increased GR expression at diagnosis is associated with a decreased risk of dying relative to those with lower levels of expression.
Insights
Higher glucocorticoid receptor (GR) expression in multiple myeloma (MM) patients at diagnosis is linked to a reduced risk of mortality. This finding offers insights into potential prognostic markers for this blood cancer.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Multiple myeloma (MM) is a plasma cell neoplasia with common relapse and treatment resistance issues.
- Current MM treatments include stem cell transplant, proteasome inhibitors, and immunomodulatory drugs.
- Dexamethasone (Dex), a synthetic steroid, enhances MM treatment by activating the glucocorticoid receptor (GR), inducing apoptosis.
Purpose of the Study:
- To investigate the association between glucocorticoid receptor (GR) expression levels at diagnosis and overall survival in multiple myeloma (MM) patients.
- To determine if GR expression can serve as a prognostic biomarker in MM.
Main Methods:
- Analysis of patient data from the CoMMpass study, including 650 multiple myeloma patients.
- Utilizing multivariate modeling to assess the relationship between GR expression and survival outcomes.
Main Results:
- Increased GR expression at diagnosis was significantly associated with a decreased risk of mortality in MM patients.
- Patients with higher GR levels exhibited better overall survival compared to those with lower GR levels.
Conclusions:
- Glucocorticoid receptor (GR) expression at diagnosis is a potential predictive biomarker for overall survival in multiple myeloma (MM).
- These findings may inform risk stratification and treatment strategies for MM patients.
